Ann: Comment on research report, page-155

Keep in mind that Acadia has multiple drugs and revenue sources and NEU has one. So of course any hit to DAYBUE revenue affects NEU proportionally more than Acadia. Plus NEU is priced for ongoing growth; Acadia less so. It’s not a questions of sophistication or manipulation, just basic finance.

you can easily google up DAYBUE user Facebook groups and find reports of adverse side effects (almost all diarrhoea); this was a known side effect for a proportion of users. Some have had the side effect and then discovered work arounds, for some carers it was too much to deal with, for some the benefits outweigh the problems. The report really said nothing new other than the assertion the number of users ceasing were higher than reported

exactly how many ceased and how many continued (or started) we will find out within a few days. Given how close it is to reporting, you have to think Acadia knows pretty accurately the sales revenue for the last reporting period and so it should come in close to what it says. Question is probably whether revenue is trending down, which might be a concern for a new drug - you would expect it to go up as more users decide to take it.

like many I feel the report took known facts and put a detrimental spin on them to create a share price reaction. However when NEU is priced for growth, in todays market even a slight miss (or risk of a miss) on expectations is punished severely - NEU is not the only share to have suffered this fate.